MaxCyte, Inc. (MXCT), a cell engineering firm, said on Monday that it expects to post its fourth-quarter core revenue in the range of $8.3 million to $8.5 million, compared with $7.2 million, registered for the same period last year. For the full year, according to the company's preliminary estimates, core revenue is expected to be in the range of $32.2 million to $32.4 million, higher than $29.8 million of the prior year.
Maher Masoud, CEO of MaxCyte, said: "The operating environment in the cell therapy industry is improving as we move into 2025, and we remain confident in the opportunity that exists for MaxCyte in the years ahead. In 2024, we increased the number of SPL customers by six, supported the commercial launch of the first non-viral gene-edited cell therapy product approved by the FDA, and returned to healthy revenue growth while streamlining operations."
The company is expected to release its full-year SPL program-related revenue and total revenue in March.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.